Personalized medicine in action: Invention of crizotinib (PF-02341066)

被引：0
|
作者：
Cui, J. Jean [1 ]
机构：
[1] Pfizer Inc, Oncol Med Chem, San Diego, CA 92130 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2012年 / 244卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
3-MEDI
引用
收藏
页数：1
相关论文
共 48 条
  • [41] Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
    Ou, Sai-Hong Ignatius
    Kwak, Eunice L.
    Siwak-Tapp, Christina
    Dy, Joni
    Bergethon, Kristin
    Clark, Jeffrey W.
    Camidge, D. Ross
    Solomon, Benjamin J.
    Maki, Robert G.
    Bang, Yung-Jue
    Kim, Dong-Wan
    Christensen, James
    Tan, Weiwei
    Wilner, Keith D.
    Salgia, Ravi
    Iafrate, A. John
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 942 - 946
  • [42] New Insight in the Mechanism of Action of Rituximab: The Interferon Signature Towards Personalized Medicine
    Verweij, Cornelis L.
    Vosslamber, Saskia
    [J]. DISCOVERY MEDICINE, 2011, 12 (64) : 229 - 236
  • [43] A call to action: dermatopathology in the age of molecular testingeducation in molecular diagnostics, genomics and personalized medicine
    Murphy, Michael J.
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2013, 40 (07) : 687 - 689
  • [44] Individual differences in the effects of the ACTION-PAC intervention: an application of personalized medicine in the prevention and treatment of obesity
    Kuhlemeier, Alena
    Jaki, Thomas
    Jimenez, Elizabeth Y.
    Kong, Alberta S.
    Gill, Hope
    Chang, Chi
    Resnicow, Ken
    Wilson, Dawn K.
    Van Horn, M. Lee
    [J]. JOURNAL OF BEHAVIORAL MEDICINE, 2022, 45 (02) : 211 - 226
  • [45] Individual differences in the effects of the ACTION-PAC intervention: an application of personalized medicine in the prevention and treatment of obesity
    Alena Kuhlemeier
    Thomas Jaki
    Elizabeth Y. Jimenez
    Alberta S. Kong
    Hope Gill
    Chi Chang
    Ken Resnicow
    Dawn K. Wilson
    M. Lee Van Horn
    [J]. Journal of Behavioral Medicine, 2022, 45 : 211 - 226
  • [46] Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action
    Bayes-Genis, Antoni
    Voors, Adriaan A.
    Zannad, Faiez
    Januzzi, James L.
    Richards, A. Mark
    Diez, Javier
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (30) : 2793 - +
  • [47] Action Recommendations to CAS and MPG on Personalized Medicine Steering Committee of the 5th Exploratory Round Table Conference
    [J]. Bulletin of the Chinese Academy of Sciences, 2015, (01) : 41 - 44
  • [48] Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action
    Dubbelman, Mark A.
    Vromen, Eleonora M.
    Tijms, Betty M.
    Berkhof, Johannes
    Ottenhoff, Lois
    Vijverberg, Everard G. B.
    Prins, Niels D.
    van der Flier, Wiesje M.
    Sikkes, Sietske A. M.
    [J]. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (03)
12345